Better Home & Finance Holding Company
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $483.4M
- Price
- $26.16
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.25%
- Volume
- 14.8K
Quote data as of 9:33 AM ET
About
Better Home & Finance Holding Company operates as a U.S.-based enterprise dedicated to various facets of homeownership. The company provides a comprehensive suite of mortgage products, including Government-Sponsored Enterprise (GSE) conforming loans, FHA-insured loans, VA-guaranteed loans, and jumbo loans. These lending solutions are offered to a diverse client base that encompasses GSEs, banks, insurance providers, asset managers, and mortgage real estate investment trusts. Additionally, its service portfolio extends to real estate agency, title insurance, settlement coordination, and homeowners' insurance. Formerly known as Better Mortgage Corporation, the company officially rebranded to Better Home & Finance Holding Company in August 2023. Its corporate headquarters are located in New York, New York.
Quick stats
Shares outstanding18.9M
Computed float9.0M
Float sourceUnknown
Cash runway (months)0.3
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorFinancial Services
IndustryFinancial - Mortgages
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001835856
Websitehttps://better.com
AI Summary
AI-generated4d agostandardbullishoperations updateBetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
BetterLife engaged Nucro-Technics to conduct the final GLP toxicology study for BETR-001, a non-hallucinogenic LSD derivative in development for neurological disorders.
This study is the remaining requirement for the Investigational New Drug (IND) application, which the company projects to file in Q1 2027.
BETR-001 acts as an agonist on 5-HT receptors and is initially being developed for migraine and cluster headache.